Adrafinil (Olmifon®) a French stimulant and antidepressant belongs to a unique class of drugs called “Eugeroics” (meaning good arousal).

Adrafinil helps to improve brain chemical processes without affecting heart rate or pressure and was specifically designed to treat narcolepsy (sleeping in the daytime), as such it can enhance awareness, mental clarity and alertness, allowing the individual to remain both alert and awake during the day.

Adrafinil’s unique feature is that it only arouses when stimulation is required. This is achieved by increasing the receptiveness of brain alpha-1 receptors to noradrenaline. This unique action even allows the individual to sleep if he or she so requires.

One or two tablets (300mg each) are taken twice a day, as required (also see Modafinil).

“Adrafinil changed my life giving me drive and direction.”
J.C., California

Home          to order        adrafinil research

ADRAFINIL (Olmifon®)

Adrafinil; Corn starch, modified sodic carboxymethyl-cellulose, polyvidone excipient, glycerol, magnesium steate, talc, lactose, polyoxyethylene glycol 4000, titanium dioxide, polymethly acrylate glycerol.

Information for the User
This product is a psycotonic. It is recommended for elderly patients who have difficulty staying alert and who suffer from a general slowing down of mental activity.

1. The effectiveness of Olmifon® has not yet been tested on the non-elderly.
2. This preparation contains an active ingredient, which could induce a positive result in anti-doping tests for athletes.

If you suffer from epilepsy, or serious hepatic or renal disorders, consult your doctor before taking this product. Do not hesitate to seek advice from your doctor or chemist, if there is any chance of an interaction-taking place between different medicines. Any additional treatment should be reported, especially if you are taking neuroepileptic medicines. Keep this and all other medicines safely out of the reach of children.

Side Effects
As with any active product, this medicine may possibly cause side effects. Headache, stomach pains and skin irritations have been reported in clinical tests, and in certain cases, inner tension.

2 to 4 tablets daily. Please follow your doctor’s instructions.

Prescription Conditions
This product has been prescribed for you in order to remedy a particular medical problem. Do not use it to treat other ailments. Do not use it again without first consulting your doctor. Do not use it to treat another person. Consult your doctor.

to order

A unique psychopharmacologic profile of adrafinil in mice
Rambert FA, Pessonnier J, de Sereville JE, Pointeau AM, Duteil J

The following psychopharmacological effects of adrafinil have been observed in mice: increase in locomotor activity (64-256, antagonism (16-128 of the hypnotic effects of barbitone but not of pentobarbitone, reduction of immobility duration in the forced swimming test (16-256; slight antagonism (256 of electroshock-induced convulsions; no modification of rectal temperature; no stereotyped or climbing behaviour; no increase in lethality in aggregated mice (LD50 isolated = 1022, LD50 aggregated = 859; lack of effects on the provisional tests for antidepressants: no interaction with reserpine-, oxotremorine-, or apomorphine-induced hypothermia but potentiation of yohimbine-induced toxicity; lack of peripheral sympathetic effects (no mydriasis, no salivation, no contraction of the pilomotor muscles, no antagonism of reserpine-induced ptosis); lack of peripheral anticholinergic effects (no mydriasis, no antagonism of oxotremorine-induced salivation or lacrimation). As compared to no analeptic, anticholinergic or antidepressant drugs, adrafinil shows a unique behavioural profile in mice defined on the one hand by a specific stimulant activity associated with antidepressant-like effect s that do no seem related to a beta-adrenergic mechanism and on the other hand by a lack of dopaminergic effects. Most adrafinil-induced effects (increase in locomotor activity, reduction of immobility duration in the forced swimming test) may correspond to a central alpha 1-adrenergic stimulation, but the unexpected lack of peripheral sympathetic effects remains unexplained.

PMID: 3713198, UI: 86229117

J Pharmacol 1986 Jan-Mar;17(1):37-52

to order